BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 19404022)

  • 1. [Multiple myeloma relapsed or progressed as plasmacytoma after allogeneic reduced-intensity stem cell transplantation: report of three cases].
    Sugimoto Y; Nishii K; Miyata E; Fujieda A; Yamaguchi M; Masuya M; Katayama N
    Rinsho Ketsueki; 2009 Apr; 50(4):289-94. PubMed ID: 19404022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
    Hayashi T; Yasui H; Kawakami K; Ikeda H; Takahashi F; Kobayashi T; Nishimura S; Ishida T; Imai K; Shinomura Y
    Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission.
    Byrne JL; Fairbairn J; Davy B; Carter IG; Bessell EM; Russell NH
    Bone Marrow Transplant; 2003 Feb; 31(3):157-61. PubMed ID: 12621475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonmyeloablative allogeneic peripheral blood stem cell transplantation for multifocal extramedullary plasmacytomas progressing after autologous transplantation.
    Ornstein DL; Ririe DW; Shaughnessy PJ; Neuhauser T; Bee C
    Bone Marrow Transplant; 2002 Jan; 29(1):71-4. PubMed ID: 11840148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of allogeneic stem cell transplantation in multiple myeloma.
    Bruno B; Giaccone L; Sorasio R; Boccadoro M
    Semin Hematol; 2009 Apr; 46(2):158-65. PubMed ID: 19389499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect.
    Zeiser R; Finke J
    Eur J Cancer; 2006 Jul; 42(11):1601-11. PubMed ID: 16759847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation.
    Lee CK; Zangari M; Fassas A; Thertulien R; Talamo G; Badros A; Cottler-Fox M; van Rhee F; Barlogie B; Tricot G
    Bone Marrow Transplant; 2006 Mar; 37(5):511-5. PubMed ID: 16435020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review.
    Hahn T; Wingard JR; Anderson KC; Bensinger WI; Berenson JR; Brozeit G; Carver JR; Kyle RA; McCarthy PL
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):4-37. PubMed ID: 12533739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of allogeneic stem cell transplantation in multiple myeloma.
    Thomson KJ; Peggs KS
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):455-64. PubMed ID: 16001953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft-versus-myeloma.
    Mehta J; Singhal S
    Bone Marrow Transplant; 1998 Nov; 22(9):835-43. PubMed ID: 9827810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and molecular remission following reduced intensity conditioning and allogeneic transplantation in a patient with refractory multiple myeloma.
    Dodero A; Perfetti V; Ciceri F; Corradini P
    Haematologica; 2002 Dec; 87(12):ECR41. PubMed ID: 12495912
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of stem cell transplantation.
    Harousseau JL
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1157-74, x. PubMed ID: 17996593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early recurrence of rheumatoid arthritis after nonmyeloablative allogeneic blood stem cell transplantation in a patient with multiple myeloma.
    Tapprich C; Fenk R; Schneider P; Bernhardt A; Haas R; Kobbe G
    Bone Marrow Transplant; 2003 Sep; 32(6):629-31. PubMed ID: 12953137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation.
    Thomson KJ; Peggs KS; Smith P; Cavet J; Hunter A; Parker A; Pettengell R; Milligan D; Morris EC; Goldstone AH; Linch DC; Mackinnon S
    Bone Marrow Transplant; 2008 May; 41(9):765-70. PubMed ID: 18195684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).
    Mohty M; Attal M; Marit G; Bulabois CE; Garban F; Gratecos N; Rio B; Vernant JP; Sotto JJ; Cahn JY; Blaise D; Jouet JP; Facon T; Yakoub-Agha I
    Bone Marrow Transplant; 2005 Jan; 35(2):165-9. PubMed ID: 15531895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect.
    Khaled Y; Mellacheruvu S; Reddy P; Peres E; Mineishi S
    Bone Marrow Transplant; 2009 Sep; 44(5):325-6. PubMed ID: 19204708
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma.
    Terpos E; Rezvani K; Basu S; Milne AE; Rose PE; Scott GL; Rahemtulla A; Samson D; Apperley JF
    Eur J Haematol; 2005 Nov; 75(5):376-83. PubMed ID: 16191086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic microangiopathy after combined autografting-allografting for multiple myeloma - report of three cases.
    Kornacker M; Luft T; Ho AD; Schaefer HJ
    Eur J Haematol; 2005 Mar; 74(3):250-3. PubMed ID: 15693795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autografting followed by a reduced-intensity conditioning unrelated donor cord blood transplantation for a patient with refractory multiple myeloma: successful engraftment with minimal toxicity.
    Ando T; Yujiri T; Tominaga T; Shinya S; Takahashi T; Nomiyama J; Seguchi M; Matsubara A; Fujii Y; Tanizawa Y
    Eur J Haematol; 2005 Feb; 74(2):175-9. PubMed ID: 15654912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation.
    Voena C; Malnati M; Majolino I; Fagà G; Montefusco V; Farina L; Santoro A; Ladetto M; Boccadoro M; Corradini P
    Bone Marrow Transplant; 2003 Oct; 32(8):791-3. PubMed ID: 14520423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.